Late-Line R/R: Treatment Landscape
Panelists discuss the transformative impact of chimeric antigen receptor (CAR) T-cell therapy on treating relapsed/refractory multiple myeloma (R/R MM) in real-world settings, emphasizing improved patient outcomes, the expanding role of real-world evidence, and the nuanced decision-making required in selecting among newly approved, highly effective immunotherapies.
EP: 1.Late-Line R/R: Treatment Landscape
EP: 2.Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
EP: 3.Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma
EP: 4.Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
EP: 5.Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
EP: 6.Role of CAR T in Earlier Lines for R/R MM
EP: 7.Non-ICANS and Delayed Neurotoxicity With CAR T: Risk Factors and Ways to Prevent
EP: 8.Real-World Data of SOC Cilta-Cel in R/R MM and Cilta-Cel in Patients With High-Risk Features
EP: 9.Identifying and Treating Patients With Adverse Prognostic Factors
EP: 10.Supportive Care: Infection Disease Prophylaxis and Advice for Community Doctors
EP: 11.Best Practices for Referring Patients for CAR T Therapy
This discussion centers on the use of CAR T-cell therapy for treating MM, especially in real-world settings that include patients often excluded from clinical trials. Experts from leading cancer centers convene to share their experiences, data, and perspectives on using this therapy in advanced cases of the disease. The conversation highlights the evolving nature of myeloma treatment and the growing importance of real-world evidence in shaping treatment decisions outside of traditional clinical parameters.
One key theme is the dramatic improvement in outcomes for patients with R/R MM, particularly those who have exhausted conventional therapies. Just a few years ago, such patients had very limited options, with progression-free survival and overall survival measured in mere months. The approval of 5 new immunotherapies, including 2 B-cell maturation antigen–targeting CAR T-cell products and 3 bispecific antibodies, has significantly transformed the treatment landscape. These therapies have shown remarkable efficacy and are now the preferred approach for patients who are triple- or even penta-class refractory.
The panel emphasizes that choosing the right therapy—whether CAR T-cell or bispecific antibodies—requires careful consideration of factors like toxicity, patient fitness, and logistics. Clinicians now face a new challenge: selecting from multiple highly effective treatments rather than working with limited options. The discussion is grounded in recent collaborative data that underscore the safety and effectiveness of CAR T therapies, even in populations not typically eligible for trials. This shift represents a major advancement in the care of MM, offering new hope and improved outcomes for patients with otherwise limited options.
